Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification
Cet article examine la place de l'hormonothérapie dans le traitement des cancers de l'endomètre
Endometrial cancer (EC) is currently the sixth most common malignancy in women worldwide, accounting for approximately 97,000 deaths per year and with rapidly increasing incidence.1 EC can be characterized based on molecular signatures into four prognostically distinct subgroups2-4: (1) ultramutated tumors characterized by POLE hotspot mutations with excellent prognosis; (2) hypermutated tumors characterized by mismatch repair deficiency (MMRd) resulting in microsatellite instability (MSI) with intermediate prognosis; (3) tumors with no specific molecular profile (NSMP) or copy-number low (p53 wild-type) with intermediate prognosis; and (4) copy-number high (CNH) tumors, characterized by TP53 mutations (p53abn) and poor prognosis.
Journal of Clinical Oncology , article en libre accès, 2022